Tyrah Hickman
Psychiatric/Mental Health · Jackson, MSNPI 1932735727
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,866 and has fallen 50.5% since, to $925 in 2025. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $41.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$852
- Vanda Pharmaceuticals Inc.$539
- Neurocrine Biosciences, Inc.$535
- Otsuka America Pharmaceutical, Inc.$474
- Johnson & Johnson$430
- AbbVie$331
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,08199%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 22 | $852 |
| Vanda Pharmaceuticals Inc. | 15 | $539 |
| Neurocrine Biosciences, Inc. | 14 | $535 |
| Otsuka America Pharmaceutical, Inc. | 11 | $474 |
| Johnson & Johnson | 16 | $430 |
| AbbVie | 8 | $331 |
| Axsome Therapeutics, Inc. | 3 | $320 |
| AstraZeneca(2 entities) | 2 | $255 |
| Gilead | 2 | $250 |
| Indivior Inc. | 12 | $192 |
| Avanir Pharmaceuticals, Inc. | 2 | $145 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Novo Nordisk | 2 | $132 |
| Astellas Pharma Global Development | 1 | $130 |
| Supernus Pharmaceuticals, Inc. | 1 | $123 |
| Kyowa Kirin, Inc. | 1 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Viiv Healthcare Company | 1 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Merck | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,467
- ARISTADA$473
- Biktarvy$250
- INGREZZA$250
- VRAYLAR$248
- ABILIFY ASIMTUFII$247
- ABILIFY MAINTENA$247
- Fanapt$246
- Veozah$130
- Auvelity$125
- FARXIGA$125
- NUEDEXTA$125
- QELBREE$123
- ARISTADA INITIO$118
- COBENFY$113
- Wegovy$104
- INVEGA SUSTENNA$101
How this compares
$5,108 in reported general payments places this provider in the 90th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 16 | $57,068 |
| Quetiapine Fumarate | 13 | $420 |
| Trazodone Hcl | 45 | $330 |
| Aripiprazole | 11 | $321 |
| Hydroxyzine Pamoate | 29 | $303 |
| Risperidone | 23 | $294 |
| Fluoxetine Hcl | 11 | $59 |
| Sertraline Hcl | 18 | $57 |
| Alprazolam | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $430 | $57,06816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Jackson
- Alanna WrightJackson$58K
- Belinda EdwardsJackson$29K
- Kimberly KelleyJackson$11K
- Min Jung KangJackson$5K
- Adriane HarveyJackson$5K
- Brandy RutlandJackson$4K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.